• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Polygenic Risk and Coronary Artery Disease Severity.多基因风险与冠状动脉疾病严重程度。
Circ Genom Precis Med. 2024 Oct;17(5):e004470. doi: 10.1161/CIRCGEN.123.004470. Epub 2024 Aug 8.
2
Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease.单基因与多基因高胆固醇血症与动脉粥样硬化性心血管疾病风险的关联。
JAMA Cardiol. 2020 Apr 1;5(4):390-399. doi: 10.1001/jamacardio.2019.5954.
3
The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.载脂蛋白(a)和前蛋白转化酶枯草溶菌素 9 与家族性高胆固醇血症患者动脉粥样硬化病变的存在及严重程度的关系。
Atherosclerosis. 2018 Oct;277:7-14. doi: 10.1016/j.atherosclerosis.2018.07.030. Epub 2018 Jul 26.
4
Genomic Drivers of Coronary Artery Disease and Risk of Future Outcomes After Coronary Angiography.冠状动脉疾病的基因组驱动因素与冠状动脉造影术后未来结局的风险
JAMA Netw Open. 2025 Jan 2;8(1):e2455368. doi: 10.1001/jamanetworkopen.2024.55368.
5
SYNTAX I score is associated with genetically confirmed familial hypercholesterolemia in chinese patients with coronary heart disease.SYNTAX I评分与经基因确诊的中国冠心病患者家族性高胆固醇血症相关。
BMC Cardiovasc Disord. 2024 Dec 21;24(1):737. doi: 10.1186/s12872-024-04428-3.
6
Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction.对早发性心肌梗死家族中与家族性高胆固醇血症相关变异的系统分析。
Eur J Hum Genet. 2016 Feb;24(2):191-7. doi: 10.1038/ejhg.2015.100. Epub 2015 Jun 3.
7
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.在 ODYSSEY OUTCOMES 试验中,具有高全基因组多基因风险评分的冠心病患者可能从阿利西尤单抗治疗中获得更大的临床获益。
Circulation. 2020 Feb 25;141(8):624-636. doi: 10.1161/CIRCULATIONAHA.119.044434. Epub 2019 Nov 11.
8
Polygenic Risk, Rare Variants, and Family History: Independent and Additive Effects on Coronary Heart Disease.多基因风险、罕见变异与家族史:对冠心病的独立和累加效应
JACC Adv. 2023 Aug 26;2(7):100567. doi: 10.1016/j.jacadv.2023.100567. eCollection 2023 Sep.
9
Subtyping Severe Hypercholesterolemia by Genetic Determinant to Stratify Risk of Coronary Artery Disease.基于遗传标志物对严重高胆固醇血症进行亚型分类,以分层冠状动脉疾病风险。
Arterioscler Thromb Vasc Biol. 2023 Oct;43(10):2058-2067. doi: 10.1161/ATVBAHA.123.319341. Epub 2023 Aug 17.
10
Whole-Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial Infarction.全基因组测序分析早发性心肌梗死住院患者中单基因和多基因的作用。
Circulation. 2019 Mar 26;139(13):1593-1602. doi: 10.1161/CIRCULATIONAHA.118.035658.

引用本文的文献

1
Application of nanoultrasonography in early diagnosis of coronary heart disease.纳米超声心动图在冠心病早期诊断中的应用。
Nanomedicine (Lond). 2025 Jan;20(1):79-89. doi: 10.1080/17435889.2024.2435255. Epub 2024 Dec 5.

本文引用的文献

1
A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease.多血统多基因风险评分可提高冠心病风险预测。
Nat Med. 2023 Jul;29(7):1793-1803. doi: 10.1038/s41591-023-02429-x. Epub 2023 Jul 6.
2
Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants.在超过 100 万名参与者中发现并系统地描述了冠心病的风险变异和基因。
Nat Genet. 2022 Dec;54(12):1803-1815. doi: 10.1038/s41588-022-01233-6. Epub 2022 Dec 6.
3
Large-scale genome-wide association study of coronary artery disease in genetically diverse populations.大规模全基因组关联研究在遗传多样化人群中的冠状动脉疾病。
Nat Med. 2022 Aug;28(8):1679-1692. doi: 10.1038/s41591-022-01891-3. Epub 2022 Aug 1.
4
Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease.全基因组分析提供了遗传证据,表明 ACE2 影响 COVID-19 风险,并产生与严重疾病相关的风险评分。
Nat Genet. 2022 Apr;54(4):382-392. doi: 10.1038/s41588-021-01006-7. Epub 2022 Mar 3.
5
The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation.多基因风险评分目录作为一个开放的数据库,用于可重复性和系统评估。
Nat Genet. 2021 Apr;53(4):420-425. doi: 10.1038/s41588-021-00783-5.
6
Genome-wide analysis identifies novel susceptibility loci for myocardial infarction.全基因组分析鉴定出心肌梗死的新易感位点。
Eur Heart J. 2021 Mar 1;42(9):919-933. doi: 10.1093/eurheartj/ehaa1040.
7
Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions.多基因背景会影响一级基因组条件中单基因变异的外显率。
Nat Commun. 2020 Aug 20;11(1):3635. doi: 10.1038/s41467-020-17374-3.
8
Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk: Clinical Perspectives and Basic Implications.多基因风险评分评估动脉粥样硬化性心血管疾病风险:临床观点和基本意义。
Circ Res. 2020 Apr 24;126(9):1159-1177. doi: 10.1161/CIRCRESAHA.120.315928. Epub 2020 Apr 23.
9
Polygenic risk scores for coronary artery disease and subsequent event risk amongst established cases.多基因风险评分与已确诊冠心病患者的后续发病风险。
Hum Mol Genet. 2020 May 28;29(8):1388-1395. doi: 10.1093/hmg/ddaa052.
10
Polygenic risk for coronary heart disease acts through atherosclerosis in type 2 diabetes.多基因冠心病风险通过 2 型糖尿病的动脉粥样硬化起作用。
Cardiovasc Diabetol. 2020 Jan 30;19(1):12. doi: 10.1186/s12933-020-0988-9.

多基因风险与冠状动脉疾病严重程度。

Polygenic Risk and Coronary Artery Disease Severity.

机构信息

Department of Cardiovascular Medicine (A.S., K.N., M.N., I.J.K.).

Department of Health Sciences Research (D.J.S.).

出版信息

Circ Genom Precis Med. 2024 Oct;17(5):e004470. doi: 10.1161/CIRCGEN.123.004470. Epub 2024 Aug 8.

DOI:10.1161/CIRCGEN.123.004470
PMID:39114909
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11971913/
Abstract

BACKGROUND

Coronary atherosclerotic burden and adverse coronary heart disease events are related phenotypes with likely shared genetic cause.

METHODS

We analyzed 6021 patients with available coronary angiography, genotyping, and exome sequencing data. We tested for associations of polygenic risk scores for coronary heart disease (PRS) with multiple measures of coronary artery disease (CAD) severity. We assessed the joint associations of PRS and pathogenic/likely pathogenic variants in 3 familial hypercholesterolemia genes, with CAD severity. We performed mediation analyses to explore whether CAD severity mediated the association of PRS with prevalent coronary heart disease and incident myocardial infarction.

RESULTS

A 1-SD increase in PRS was associated with multiple measures of CAD severity, including the log Gensini score (β, 0.31 [95% CI, 0.28-0.33]). Carrying a pathogenic/likely pathogenic familial hypercholesterolemia variant was associated with a higher log Gensini score after adjustment for PRS (β, 0.21 [95% CI, 0.03-0.38]). A 1-SD increase in PRS was associated with incident myocardial infarction over a mean follow-up of 9.2 years (hazard ratio, 1.20 [95% CI, 1.13-1.27]; =5×10), and the Gensini score mediated 90% of this association.

CONCLUSIONS

PRS was associated with multiple measures of CAD severity. The association of PRS with incident myocardial infarction was almost fully mediated by CAD severity, indicating a considerable genetic overlap between the 2 phenotypes.

摘要

背景

冠状动脉粥样硬化负担和不良冠心病事件是相关表型,可能有共同的遗传原因。

方法

我们分析了 6021 名有冠状动脉造影、基因分型和外显子组测序数据的患者。我们检测了冠心病多基因风险评分(PRS)与多种冠状动脉疾病(CAD)严重程度指标之间的关联。我们评估了 PRS 与 3 个家族性高胆固醇血症基因中的致病性/可能致病性变异与 CAD 严重程度的联合关联。我们进行了中介分析,以探讨 CAD 严重程度是否介导了 PRS 与冠心病和心肌梗死发病的相关性。

结果

PRS 每增加 1 个标准差与 CAD 严重程度的多个指标相关,包括 Gensini 评分对数(β,0.31 [95% CI,0.28-0.33])。校正 PRS 后,携带致病性/可能致病性家族性高胆固醇血症变异与 Gensini 评分对数升高相关(β,0.21 [95% CI,0.03-0.38])。PRS 每增加 1 个标准差与平均随访 9.2 年后的心肌梗死发病相关(风险比,1.20 [95% CI,1.13-1.27];=5×10),Gensini 评分介导了这种关联的 90%。

结论

PRS 与 CAD 严重程度的多个指标相关。PRS 与心肌梗死发病的相关性几乎完全由 CAD 严重程度介导,表明这两种表型之间存在相当大的遗传重叠。